LUMISIGHT

Growth

pegulicianine

NDAINTRAVENOUSPOWDERPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100

Mechanism of Action

12.1 Mechanism of Action Pegulicianine is a prodrug that is optically inactive when intact and produces a fluorescent signal after its peptide chain is cleaved by cathepsins and matrix metalloproteases (MMPs). The levels of these enzymes are higher in and around tumor and tumor-associated cells…

Indications (1)

Loss of Exclusivity

LOE Date
Sep 14, 2034
103 months away
Patent Expiry
Sep 14, 2034
Exclusivity Expiry
Apr 17, 2029

Patent Records (5)

Patent #ExpiryTypeUse Code
11592396
Sep 1, 2030
Substance
9155471
Oct 12, 2031
U-3890
10285759
Dec 8, 2031
U-3890
9032965
Dec 8, 2031
U-3890
9532835
Dec 8, 2031
U-3890